AET Pharma US Inc. announces successful approval of Abbreviated New Drug Application (ANDA) for Posaconazole

On 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole in 100 mg Delayed-Release Tablets. This is another milestone for TIEFENBACHER GROUP in further strengthening its product portfolio in the United States. The US launch of Posaconazole will proceed in close cooperation with our experienced distribution partner, Lupin Pharmaceuticals Inc. With the market entry of Posaconazole, we look forward to increasing availability and ensuring affordability of this treatment for American patients.

The product has been developed by and is manufactured at TIEFENBACHER LABORATORIES in Hyderabad, India, and has already been successfully launched in the European Union and in Australia. The registration dossier is currently under filing in several additional international markets.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or please visit us on: www.tiefenbacher-pharmaceuticals.com

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com